Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995255315> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- W2995255315 endingPage "S789" @default.
- W2995255315 startingPage "S789" @default.
- W2995255315 abstract "Three levels of RPGs exist in Germany: (1) drugs with the same active compound, (2) drugs with pharmacological-therapeutically and chemically comparable active compounds, (3) drugs with different active compounds that are therapeutically comparable. Patent protected drugs may be incorporated into a RPG of level 2 or 3 (`jumbo groups`). There is no standardized process for the time from announcement of a new RPG up to the time when a new price is set. Aim of this study was to analyze historical durations for each procedural step and to evaluate possible influencing factors. New RPGs of the last 10 years (cut date April 1, 2019) were analyzed including a qualitative assessment of argumentations by manufacturers from procedural/written statements. In total, n=72 RPGs were analyzed: 53/72 for level 1, 7/72 for level 2, and 12/72 level 3. It took 1.5 years from announcement of a new RPG until setting of the new (reduced) price. For level 1 the mean duration until publication of a RPG was 16 months (range 8-29), level 2 19 months (range 14-26), and level 3 18 months (range 11-26). Still patented drugs were included in 4 of 7 RPGs (57%) in level 2 and in 6 of 12 RPGs (50%) in level 3. Main discussion points, extracted from statements, circled around therapeutic improvements, criticism regarding the methodology applied in the calculation of the RPG and choice of the standard package. There was no correlation between intensity of the discussion and time to price setting. Building jumbo groups may discriminate innovative pharmaceuticals in pricing. Most patients will not be willing to pay the difference between retail price and reference price. Therefore, pharmaceutical companies need to develop strategies for market differentiation as early as possible to avoid price discrimination for a patent protected drug." @default.
- W2995255315 created "2019-12-26" @default.
- W2995255315 creator A5060100596 @default.
- W2995255315 creator A5063341288 @default.
- W2995255315 creator A5074188740 @default.
- W2995255315 date "2019-11-01" @default.
- W2995255315 modified "2023-09-30" @default.
- W2995255315 title "PNS168 REFERENCE PRICE GROUPS (RPG) DEFINED FROM 2008 TO 2018 IN GERMANY - A DETAILED OVERVIEW AND DISCUSSION" @default.
- W2995255315 doi "https://doi.org/10.1016/j.jval.2019.09.2068" @default.
- W2995255315 hasPublicationYear "2019" @default.
- W2995255315 type Work @default.
- W2995255315 sameAs 2995255315 @default.
- W2995255315 citedByCount "0" @default.
- W2995255315 crossrefType "journal-article" @default.
- W2995255315 hasAuthorship W2995255315A5060100596 @default.
- W2995255315 hasAuthorship W2995255315A5063341288 @default.
- W2995255315 hasAuthorship W2995255315A5074188740 @default.
- W2995255315 hasBestOaLocation W29952553151 @default.
- W2995255315 hasConcept C71924100 @default.
- W2995255315 hasConceptScore W2995255315C71924100 @default.
- W2995255315 hasLocation W29952553151 @default.
- W2995255315 hasOpenAccess W2995255315 @default.
- W2995255315 hasPrimaryLocation W29952553151 @default.
- W2995255315 hasRelatedWork W1506200166 @default.
- W2995255315 hasRelatedWork W1995515455 @default.
- W2995255315 hasRelatedWork W2048182022 @default.
- W2995255315 hasRelatedWork W2080531066 @default.
- W2995255315 hasRelatedWork W2604872355 @default.
- W2995255315 hasRelatedWork W2748952813 @default.
- W2995255315 hasRelatedWork W2899084033 @default.
- W2995255315 hasRelatedWork W3031052312 @default.
- W2995255315 hasRelatedWork W3032375762 @default.
- W2995255315 hasRelatedWork W3108674512 @default.
- W2995255315 hasVolume "22" @default.
- W2995255315 isParatext "false" @default.
- W2995255315 isRetracted "false" @default.
- W2995255315 magId "2995255315" @default.
- W2995255315 workType "article" @default.